Lineage Cell Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

LCTX$1.08+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Shareholders' Equity

Three Months Ended June 30, 2024
Accumulated
Common · Other · Total
Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - March 31, 2024	188,754	$466,571	$(391,398)	$(1,412)	$(2,771)	$70,990
Shares issued through ATM	26	33	—	—	—	33
Financing related fees	—	(1)	—	—	—	(1)
Shares issued upon exercise of stock options	44	56	—	—	—	56
Stock-based compensation	—	1,269	—	—	—	1,269
Unrealized loss on marketable debt securities	—	—	—	—	(6)	(6)
Foreign currency translation adjustment	—	—	—	—	307	307
Net loss	—	—	(5,760)	(13)	—	(5,773)
BALANCE - June 30, 2024	188,824	$467,928	$(397,158)	$(1,425)	$(2,470)	$66,875

Three Months Ended June 30, 2023
Accumulated
Common · Other · Total
Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - March 31, 2023	170,174	$441,299	$(367,742)	$(1,435)	$(3,107)	$69,015
Shares issued through ATM	4,237	5,841	—	—	—	5,841
Financing related fees	—	(193)	—	—	—	(193)
Shares issued upon exercise of stock options	28	22	—	—	—	22
Stock-based compensation	—	1,280	—	—	—	1,280
Unrealized gain on marketable debt securities	—	—	—	—	50	50
Foreign currency translation adjustment	—	—	—	—	446	446
Net loss	—	—	(5,229)	26	—	(5,203)
BALANCE - June 30, 2023	174,439	$448,249	$(372,971)	$(1,409)	$(2,611)	$71,258

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (CONTINUED)

Six Months Ended June 30, 2024
Accumulated
Common · Other · Total
Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2023	174,987	$451,343	$(384,856)	$(1,396)	$(3,068)	$62,023
Shares issued through registered direct financing	13,462	14,000	—	—	—	14,000
Shares issued through ATM	56	70	—	—	—	70
Financing related fees	—	(113)	—	—	—	(113)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	45	(23)	—	—	—	(23)
Shares issued upon exercise of stock options	274	219	—	—	—	219
Stock-based compensation	—	2,432	—	—	—	2,432
Unrealized loss on marketable debt securities	—	—	—	—	(7)	(7)
Foreign currency translation adjustment	—	—	—	—	605	605
Net loss	—	—	(12,302)	(29)	—	(12,331)
BALANCE - June 30, 2024	188,824	$467,928	$(397,158)	$(1,425)	$(2,470)	$66,875

Six Months Ended June 30, 2023
Accumulated
Common · Other · Total
Shares · Accumulated · Noncontrolling · Comprehensive · Shareholders’
	Shares	Amount	Deficit	Deficit	Income / (Loss)	Equity
BALANCE - December 31, 2022	170,093	$440,280	$(363,370)	$(1,403)	$(3,571)	$71,936
Shares issued through ATM	4,237	5,841	—	—	—	5,841
Financing related fees	—	(193)	—	—	—	(193)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes	53	(37)	—	—	—	(37)
Shares issued upon exercise of stock options	56	47	—	—	—	47
Stock-based compensation	—	2,311	—	—	—	2,311
Unrealized gain on marketable debt securities	—	—	—	—	141	141
Foreign currency translation adjustment	—	—	—	—	819	819
Net loss	—	—	(9,601)	(6)	—	(9,607)
BALANCE - June 30, 2023	174,439	$448,249	$(372,971)	$(1,409)	$(2,611)	$71,258

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.